Health Technology · Pharmaceuticals: Major · NSE: SUNPHARMA · data 2026-10-09

Sun Pharmaceutical Industries Limited

Health check: Strong (7/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹1,760

Market cap

₹4,20,474 cr

P/E

34.9

P/B

—

ROE

14.7%

ROCE

17.7%

Debt / equity

0.06

Dividend yield

0.91%

1-year return

7.0%

52-week high

₹2,046.9

52-week low

₹1,583.7

Operating margin

22.9%

Growth

Revenue (last 12 months)	₹59,911 cr
Net profit (last 12 months)	₹12,096 cr
Sales growth, 3 years (yearly)	9.9%
Profit growth, 3 years (yearly)	10.6%

Similar companies

Divi's Laboratories Limited (DIVISLAB) · Torrent Pharmaceuticals Ltd (TORNTPHARM) · Zydus Lifesciences Limited (ZYDUSLIFE) · Laurus Labs Ltd. (LAURUSLABS) · Mankind Pharma Ltd. (MANKIND)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open SUNPHARMA in NSE Scanner →